Innovent Biologics, Inc. (HKG:1801)

Market Cap	85.21B
Revenue (ttm)	10.03B
Net Income (ttm)	-100.70M
Shares Out	1.65B
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	208.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,146,055
Average Volume	23,590,481
Open	51.00
Previous Close	51.70
Day's Range	50.55 - 53.05
52-Week Range	28.65 - 56.10
Beta	0.28
RSI	56.65
Earnings Date	Aug 22, 2025

About Innovent Biologics

Innovent Biologics, Inc., a biopharmaceutical company, develops, manufactures and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully human antiTNF-α monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 5,659
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1801

Financial Performance

In 2024, Innovent Biologics's revenue was 9.42 billion, an increase of 51.82% compared to the previous year's 6.21 billion. Losses were -94.63 million, -90.79% less than in 2023.

Financial numbers in CNY